Guías Clínicas
98
Guías tam izaje, d iagn óstico y tratam ien to de l hepa toca rcinoma - Sociedad Chilena de Gastroenterología
O. Current Role of Ultrasound for
the Management of Hepatocellular
Carcinoma. World J Gastroenterol.
2008;14:1710-9.
49.- Dodd GD, Miller WJ, Baron RL,
Skolnick ML, Campbell WL. Detection
of Malignant Tumors in End-Stage
Cirrhotic Livers: Efficacy of Sonography
as a Screening Technique. Am J
Roentgenol. 1992;159:727-33.
50.- Shapiro RS, Katz R, Mendelson DS,
Halton KP, Schwartz ME, Miller CM.
Detection of Hepatocellular Carcinoma
in Cirrhotic Patients: Sensitivity of CT
and Ultrasonography. J Ultrasound Med.
1996;15:497-502.
51.- Takayasu K, Moriyama N, Muramatsu
Y, Makuuchi M, Hasegawa H, Okazaki
N, et al. The Diagnosis of Small
Hepatocellular Carcinomas: Efficacy
of Various Imaging Procedures in 100
patients. Am J Roentgenol. 1990;155:49-
54.
52.- Chan Kyo K, Jae Hoon L, Won Jae L.
Detection of Hepatocellular Carcinomas
and Dysplastic Nodules in Cirrhotic
Liver. J Ultrasound Med. 2001;20:99-
104.
53.- Huang J, Chen W, Yao S. Assessing
Diagnostic Value of Contrast-Enhanced
Ultrasound and Contrast-Enhanced
Computed Tomography in Detecting
Small Hepatocellular Carcinoma. Med
(United States). 2017;96:e7555.
54.- Di Martino M, De Filippis G, De Santis
A, Geiger D, Del Monte M, Lombardo
CV, et al. Hepatocellular Carcinoma
in Cirrhotic Patients: Prospective
Comparison of US, CT and MR
Imaging. Eur Radiol. 2013;23:887-96.
55.- Hanna RF, Miloushev VZ, Tang A,
Finklestone LA, Brejt SZ, Sandhu RS, et
al. Comparative 13-year meta-analysis
of the Sensitivity and Positive Predictive
Value of Ultrasound, CT, and MRI for
Detecting Hepatocellular Carcinoma.
Abdom Radiol. 2016;41(1):71-90.
56.- Lee YJ, Lee JM, Lee JS, Lee HY, Park
BH, Kim YH, et al. Hepatocellular
Carcinoma: Diagnostic Performance of
Multidetector CT and MR Imaging—A
Systematic Review and Meta-Analysis.
Radiology. 2015;275:97-109.
57.- Khaled M. Elsayes, Hooker JC, Agrons
MM, Kielar AZ, Tang A, Fowler KJ, et
al. 2017 Version of LI-RADS for CT and
MR Imaging: An Update. Radiographics.
2017;37:1994-2017.
58.- Ronot M, Fouque O, Esvan M, Lebigot
J, Aubé C, Vilgrain V. Comparison of
the Accuracy of AASLD and LI-RADS
Criteria for the Non-Invasive Diagnosis
of CHC Smaller than 3 cm. J Hepatol.
2018;68:715-23.
59.- Chernyak V, Fowler KJ, Kamaya A,
Kielar AZ, Elsayes KM, Bashir MR,
et al. Liver Imaging Reporting and
Data System (LI-RADS) Version 2018:
Imaging of Hepatocellular Carcinoma
in At-Risk Patients. Radiology.
2018;289:816-30.
60.- Mcglynn KA, Petrick JL, London WT.
Global Epidemiology of Hepatocellular
Carcinoma: An Emphasis on
Demographic and Regional Variability.
Clin Liver Dis. 2015;19:223-38.
61.- Arora A, Kumar A. Treatment
Response Evaluation and Follow-up in
Hepatocellular Carcinoma. J Clin Exp
Hepatol. 2014;4:S126-9.
62.- Therasse P, Arbuck S, Eisenhauer E,
Wanders J, Kaplan R, Rubinstein L. New
Guidelines to Evaluate the Response to
Treatment in Solid Tumors. European
Organization for Research and Treatment
of Cancer, National Cancer Institute
of the United States, National Cancer
Institute of Canada. J Natl Cancer Inst.
2000;92:205-16.
63.- Shankar S, Kalra N, Bhatia A, Srinivasan
R, Singh P, Dhiman RK, et al. Role of
Diffusion Weighted Imaging (DWI)
for Hepatocellular Carcinoma (CHC)
Detection and its Grading on 3T MRI: A
Prospective Study. J Clin Exp Hepatol.
2016;6:303-10.
64.- Murakami T, Okada M, Hyodo T. CT
versus MR Imaging of Hepatocellular
Carcinoma: Toward Improved Treatment
Decisions. Magn Reson Med Sci.
2012;11:75-81.
65.- Sacks A, Peller PJ, Surasi DS, Chatburn
L, Mercier G, Subramaniam RM. Value
of PET/CT in the Management of
Primary Hepatobiliary Tumors, part 2.
Am J Roentgenol. 2011;197:260-5.
66.- Lencioni R, Llovet JM. Modified
RECIST ( mRECIST ) Assessment for
Hepatocellular Carcinoma. Semin Liver
Dis. 2010;30:52-60.
67.- Edeline J, Boucher E, Rolland Y,
Vauléon E, Pracht M, Perrin C, et
al. Comparison of Tumor Response
by Response Evaluation Criteria in
Solid Tumors (RECIST) and Modified
RECIST in Patients Treated with
Sorafenib for Hepatocellular Carcinoma.
Cancer. 2012;118:147-56.
68.- Yeo D, Choi J, Lee Y, MY P, Chun
H, Lee HG. Comparison of RECIST,
mRECIST, and Choi Criteria for Early
Response Evaluation of Hepatocellular
Carcinoma After Transarterial
Chemoembolization Using Drugeluting
Beads. J Comput Assist Tomogr.
2014;38:391-7.
69.- Raoul JL, Park JW, Kang YK, Finn RS,
Kim JS, Yeo W, et al. Using Modified
RECIST and Alpha-Fetoprotein
Levels to Assess Treatment Benefit in
Hepatocellular Carcinoma. Liver Cancer.
2014;3:439-50.
70.- Houdek Š, Büchler T, Kindlová E.
Comparison of RECIST 1.1 and
iRECIST for Response Evaluation in
Solid Tumours. Klin Onkol. 2017;30:32-
9.
71.- Bruix J, Gores GJ, Mazzaferro V.
Hepatocellular Carcinoma: Clinical
Frontiers and Perspectives. Gut.
2014;63:844-55.
72.- Sherman M. Staging for Hepatocellular
Carcinoma: An Embarrassment of
Riches. J Hepatol. 2016;64:535-6.
73.- Maida M, Orlando E, Cammà C,
Cabibbo G. Staging Systems of
Hepatocellular Carcinoma: A Review
of Literature. World J Gastroenterol.
2014;20:4141-50.
74.- Kinoshita A, Onoda H, Fushiya N, Koike
K, Nishino H, Tajiri H. Staging Systems
for Hepatocellular Carcinoma: Current
Status and Future Perspectives. World J
Hepatol. 2015;7:406-24.
75.- Duseja A. Staging of Hepatocellular
Carcinoma. J Clin Exp Hepatol.
2014;4:S74-9.
76.- Tandon P, Garcia-Tsao G. Prognostic
Indicators in Hepatocellular Carcinoma:
A Systematic Review of 72 Studies.
Liver Int. 2009;29:502-10.
77.- Okuda K, Ohtsuki T, Obata H,
Tomimatsu M, Okazaki N, Hasegawa H,
et al. Natural History of Hepatocellular
Carcinoma and Prognosis in Relation
to Treatment. Study of 850 Patients.
Cancer. 1985;56:918-28.
78.- The Cancer of the Liver Italian Program
Gastroenterol. latinoam 2019; Vol 30, Nº 2: 64-106